Neutrophil/lymphocyte ratio (NLR) may predict prognostic factor with gemcitabine/cisplatin/S-1 (GCS) for patients with advanced biliary tract cancer (MITSUBA /KHBO1401-1B).

Authors

null

Toru Otsuru

Department of Frontier Science for Cancer and Chemotherapy Osaka University Graduate School of Medicine, Osaka, Japan

Toru Otsuru , Tatsuya Ioka , Hiroaki Nagano , Etsuro Hatano , Hidetoshi Eguchi , Masashi Kanai , Shogo Kobayashi , Satoru Seo , Hideo Baba , Akinobu Taketomi , Kenichi Yoshimura

Organizations

Department of Frontier Science for Cancer and Chemotherapy Osaka University Graduate School of Medicine, Osaka, Japan, Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan, Department of Gastroenterological, Breast and Endocrine Surgery,Yamaguchi University Graduate School of Medicine, Ube, Japan, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan, Departments of Surgery Osaka Univeristy, School of Medicine, Osaka, Japan, Department of Medical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, Hokkaido University Graduate School of Medicine, Sapporo, Japan, Kyoto University Hospital, Kyoto, Japan

Research Funding

Pharmaceutical/Biotech Company

Background: There is little information available about prognostic markers of gemcitabine, cisplatin, and S-1 (GCS) in patients with advanced biliary tract cancer (aBTC). Neutrophil/lymphocyte ratio (NLR) in several cancers including aBTC was reported to be a prognostic and/or predictive factor associated with clinical outcomes. There are no data about relation between NLR and clinical outcome in patient with aBTC who underwent GCS. Methods: Baseline demographics and NLR at enrollment were retrospectively evaluated in 119 patients who received GCS treatment in MITSUBA / KHBO1401 randomized phase III trial, which showed significant superiority of GCS to GC. The clinical utility of the NLR was evaluated by receiver operating characteristic (ROC) curves, and the cutoff values for NLR were 3.7. We divided these patients based on estimated NLR, and evaluated the clinicopathological factors and survival in the two groups (NLR ≧ 3.7 or < 3.7). Results: 32 patients were in NLR ≧ 3.7group and 87 patients were in NLR < 3.7 group. The progression-free survival between two groups was not significantly different (p = 0.45). Although, the median overall survival (OS) of NLR ≧ 3.7 group was 10.4 months, while OS of NLR < 3.7 group was 18.5 months (HR 0.55, 95% confidential interval [CI] 0.36-0.87; p = 0.01).The ratio that was able to continue chemotherapy from initial administration six months later was 83.4%of NLR < 3.7 group, and 65.6% of NLR ≧ 3.7 group (p = 0.04). Conclusions: Our study confirmed that high NLR is associated with worse OS, and suggested it may be a predictive marker for GCS chemotherapy in patients with aBTC.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Gastrointestinal (Noncolorectal) Cancer: Publication Only

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Citation

J Clin Oncol 37, 2019 (suppl; abstr e15656)

DOI

10.1200/JCO.2019.37.15_suppl.e15656

Abstract #

e15656

Abstract Disclosures